Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<div>Lysine and arginine methylation are amongst the most frequent modifications on unstructured histone tails and in</div><div>combination with other modifications provide the basis for a combinatorial 'chromatin or histone code'. Recognition of modified</div><div>histone residues is accomplished in a specific manner by 'reader' domains that recognize chromatin modifications, allowing for</div><div>association with specific effector complexes that mediate chromatin functions. The methyl-lysine and methyl-arginine reader domain</div><div>protein SPINDLIN1 (SPIN1) belongs to a family of 5 human genes, and has been identified as a putative oncogene and transcriptional</div><div>co-activator. It contains three Tudor domains that are able to mediate chromatin binding. Here we report on the discovery</div><div>of a potent and selective bidentate Tudor domain inhibitor, which simultaneously engages Tudor domains 1 and 2 and effectively</div><div>competes with chromatin binding in cells. Inhibitor, chemoproteomic and knockdown studies in squamous cell carcinoma indicate</div><div>complex SPIN-mediated chromatin interactions leading to transcriptional changes in cellular differentiation processes.</div>

Original publication




Working paper

Publication Date